589 related articles for article (PubMed ID: 26804424)
1. F-BOX proteins in cancer cachexia and muscle wasting: Emerging regulators and therapeutic opportunities.
Sukari A; Muqbil I; Mohammad RM; Philip PA; Azmi AS
Semin Cancer Biol; 2016 Feb; 36():95-104. PubMed ID: 26804424
[TBL] [Abstract][Full Text] [Related]
2. Muscle-specific E3 ubiquitin ligases are involved in muscle atrophy of cancer cachexia: an in vitro and in vivo study.
Yuan L; Han J; Meng Q; Xi Q; Zhuang Q; Jiang Y; Han Y; Zhang B; Fang J; Wu G
Oncol Rep; 2015 May; 33(5):2261-8. PubMed ID: 25760630
[TBL] [Abstract][Full Text] [Related]
3. Epigallocatechin-3-gallate effectively attenuates skeletal muscle atrophy caused by cancer cachexia.
Wang H; Lai YJ; Chan YL; Li TL; Wu CJ
Cancer Lett; 2011 Jun; 305(1):40-9. PubMed ID: 21397390
[TBL] [Abstract][Full Text] [Related]
4. FBXO25, an F-box protein homologue of atrogin-1, is not induced in atrophying muscle.
Maragno AL; Baqui MM; Gomes MD
Biochim Biophys Acta; 2006 Jun; 1760(6):966-72. PubMed ID: 16714087
[TBL] [Abstract][Full Text] [Related]
5. Cachexia in the non-obese diabetic mouse is associated with CD4+ T-cell lymphopenia.
Zhao C; Wang Z; Robertson MW; Davies JD
Immunology; 2008 Sep; 125(1):48-58. PubMed ID: 18397274
[TBL] [Abstract][Full Text] [Related]
6. Smad7 gene delivery prevents muscle wasting associated with cancer cachexia in mice.
Winbanks CE; Murphy KT; Bernardo BC; Qian H; Liu Y; Sepulveda PV; Beyer C; Hagg A; Thomson RE; Chen JL; Walton KL; Loveland KL; McMullen JR; Rodgers BD; Harrison CA; Lynch GS; Gregorevic P
Sci Transl Med; 2016 Jul; 8(348):348ra98. PubMed ID: 27440729
[TBL] [Abstract][Full Text] [Related]
7. Suppression of atrogin-1 and MuRF1 prevents dexamethasone-induced atrophy of cultured myotubes.
Castillero E; Alamdari N; Lecker SH; Hasselgren PO
Metabolism; 2013 Oct; 62(10):1495-502. PubMed ID: 23866982
[TBL] [Abstract][Full Text] [Related]
8. Valproic acid attenuates skeletal muscle wasting by inhibiting C/EBPβ-regulated atrogin1 expression in cancer cachexia.
Sun R; Zhang S; Hu W; Lu X; Lou N; Yang Z; Chen S; Zhang X; Yang H
Am J Physiol Cell Physiol; 2016 Jul; 311(1):C101-15. PubMed ID: 27122162
[TBL] [Abstract][Full Text] [Related]
9. Aspartate inhibits LPS-induced MAFbx and MuRF1 expression in skeletal muscle in weaned pigs by regulating Akt, AMPKα and FOXO1.
Liu Y; Wang X; Leng W; Pi D; Tu Z; Zhu H; Shi H; Li S; Hou Y; Hu CA
Innate Immun; 2017 Jan; 23(1):34-43. PubMed ID: 28064564
[TBL] [Abstract][Full Text] [Related]
10. Molecular Pathways: Cachexia Signaling-A Targeted Approach to Cancer Treatment.
Miyamoto Y; Hanna DL; Zhang W; Baba H; Lenz HJ
Clin Cancer Res; 2016 Aug; 22(16):3999-4004. PubMed ID: 27340276
[TBL] [Abstract][Full Text] [Related]
11. Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex.
Li HH; Kedar V; Zhang C; McDonough H; Arya R; Wang DZ; Patterson C
J Clin Invest; 2004 Oct; 114(8):1058-71. PubMed ID: 15489953
[TBL] [Abstract][Full Text] [Related]
12. Signaling pathways perturbing muscle mass.
Glass DJ
Curr Opin Clin Nutr Metab Care; 2010 May; 13(3):225-9. PubMed ID: 20397318
[TBL] [Abstract][Full Text] [Related]
13. Curcumin prevents lipopolysaccharide-induced atrogin-1/MAFbx upregulation and muscle mass loss.
Jin B; Li YP
J Cell Biochem; 2007 Mar; 100(4):960-9. PubMed ID: 17131360
[TBL] [Abstract][Full Text] [Related]
14. Small molecule therapeutics targeting F-box proteins in cancer.
Liu Y; Mallampalli RK
Semin Cancer Biol; 2016 Feb; 36():105-19. PubMed ID: 26427329
[TBL] [Abstract][Full Text] [Related]
15. Elevated expression of activins promotes muscle wasting and cachexia.
Chen JL; Walton KL; Winbanks CE; Murphy KT; Thomson RE; Makanji Y; Qian H; Lynch GS; Harrison CA; Gregorevic P
FASEB J; 2014 Apr; 28(4):1711-23. PubMed ID: 24378873
[TBL] [Abstract][Full Text] [Related]
16. Mitochondrial and sarcoplasmic reticulum abnormalities in cancer cachexia: altered energetic efficiency?
Fontes-Oliveira CC; Busquets S; Toledo M; Penna F; Paz Aylwin M; Sirisi S; Silva AP; Orpí M; García A; Sette A; Inês Genovese M; Olivan M; López-Soriano FJ; Argilés JM
Biochim Biophys Acta; 2013 Mar; 1830(3):2770-8. PubMed ID: 23200745
[TBL] [Abstract][Full Text] [Related]
17. Muscle wasting in cancer.
Johns N; Stephens NA; Fearon KC
Int J Biochem Cell Biol; 2013 Oct; 45(10):2215-29. PubMed ID: 23770121
[TBL] [Abstract][Full Text] [Related]
18. SCF ubiquitin ligase-targeted therapies.
Skaar JR; Pagan JK; Pagano M
Nat Rev Drug Discov; 2014 Dec; 13(12):889-903. PubMed ID: 25394868
[TBL] [Abstract][Full Text] [Related]
19. The ubiquitin-proteasome system and skeletal muscle wasting.
Attaix D; Ventadour S; Codran A; Béchet D; Taillandier D; Combaret L
Essays Biochem; 2005; 41():173-86. PubMed ID: 16250905
[TBL] [Abstract][Full Text] [Related]
20. Involvement of F-BOX proteins in progression and development of human malignancies.
Uddin S; Bhat AA; Krishnankutty R; Mir F; Kulinski M; Mohammad RM
Semin Cancer Biol; 2016 Feb; 36():18-32. PubMed ID: 26410033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
